BioCryst to Speak at Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc., based in RESEARCH TRIANGLE PARK, N.C., announced its participation in several upcoming industry conferences. The company is scheduled to present at the 2024 Wells Fargo Healthcare Conference in Boston on September 5, the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9, and the 2024 Cantor Global Healthcare Conference in New York on September 19.

BioCryst Pharmaceuticals is a global biotechnology firm dedicated to enhancing the lives of individuals suffering from complement-mediated and other rare diseases. The company utilizes its expertise in structure-guided drug design to develop innovative oral small-molecule and protein therapeutics aimed at addressing challenging diseases. BioCryst has successfully commercialized ORLADEYO® (berotralstat), which is the first oral, once-daily plasma kallikrein inhibitor. Additionally, the company is actively progressing a pipeline of novel small-molecule and protein therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!